Pfizer

In a Phase 3 trial of more than 18,000 volunteers across three countries, a novel mRNA influenza vaccine developed by Pfizer has outperformed standard seasonal flu shots by 34.5%. It's yet another sign that this biotechnology is here to stay.

The first once-daily oral GLP-1 medication could be on shelves by this time next year, making the weight-loss drug easier to take and potentially cheaper. In the race to be the first, Novo Nordisk has scored a huge win, while Pfizer has failed again.